^
Association details:
| Biomarker: | KIT V559A + KIT N822I |
|---|---|
| Cancer: | Melanoma |
| Drug: | imatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, PDGFR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
V559A and N822I double KIT mutant melanoma with predictable response to imatinib?
Excerpt:
The current report, demonstrating at best stabilization of exon 11 V559A + exon17 N822I double-mutated melanoma with imatinib therapy, contributes to this end.
DOI:
10.1111/j.1755-148X.2010.00822.x
